葡萄糖耐受測試市場規模、佔有率、成長分析、按產品類型、按適應症、按最終用戶、按地區 - 產業預測，2025 年至 2032 年

2023 年全球葡萄糖耐受性測試市場規模價值 272 億美元，預計將從 2024 年的 288 億美元成長到 2032 年的 455.7 億美元，預測期內（2025-2032 年）的複合年成長率為 5.9%。

由於糖尿病盛行率不斷上升、技術不斷進步以及人們對照護現場（POC）血糖值檢測益處的認知不斷提高，糖尿病護理市場正在經歷顯著成長。無針血糖監測設備的推出徹底改變了糖尿病管理，為患者提供了無痛苦的選擇。臨床和實驗室標準協會最近對準確性指南進行了標準化，增強了 POC 測試的可靠性，尤其是在重症加護環境中。 2021年糖尿病患者數量估計為5.37億，預計2045年將達到7.83億。對葡萄糖診斷和快速檢測（STAT）解決方案的不斷成長的需求反映了醫療保健行業對改善患者照護、管理血糖濃度的效率和依從性的關注。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和資料資料
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管格局
• 案例研究
• 技術進步

葡萄糖耐受性測試市場規模（依產品類型）

• 市場概況
• 智慧感測器
• 血糖值檢測套組
• 米
• 測試紙
• 其他

葡萄糖耐受性測試市場規模（按疾病類型分類）

• 市場概況
• 反應性低血糖
• 糖尿病低血糖
• 妊娠糖尿病
• 胰島素抗性
• 其他

葡萄糖耐受性測試市場規模（按最終用戶分類）

• 市場概況
• 醫院
• 診所
• 診斷中心
• 其他

葡萄糖耐受性測試市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分析市場佔有率
  • 收益與前一年同期比較（2022-2024 年）

主要企業簡介

• Thermo Fisher Scientific Inc.（United States）
• Medtronic（United States）
• NIPRO（Japan）
• Trividia Health, Inc.（United States）
• Dexcom, Inc.（United States）
• Healius Limited（Australia）
• Penlan Healthcare Ltd.（United Kingdom）
• Quest Diagnostics Incorporated（United States）
• Johnson & Johnson Services, Inc.（United States）
• Abbott（United States）
• Laboratory Corporation of America Holdings（United States）
• ARUP Laboratories（United States）
• Cleveland HeartLab, Inc.（United States）
• Merck KGaA（Germany）
• Bayer AG（Germany）
• Ascensia Diabetes Care Holdings AG（Switzerland）
• E-Zlab Health Services（Canada）
• F. Hoffman-La Roche Ltd（Switzerland）
• LifeScan IP Holdings, LLC（United States）
• Sanofi（France）

結論和建議

Global Glucose Tolerance Test Market size was valued at USD 27.2 billion in 2023 and is poised to grow from USD 28.8 billion in 2024 to USD 45.57 billion by 2032, growing at a CAGR of 5.9% during the forecast period (2025-2032).

The market for diabetes care is experiencing significant growth, driven by increasing diabetes prevalence, technological advancements, and heightened awareness of point-of-care (POC) glucose testing benefits. The introduction of needle-free blood glucose monitoring devices is revolutionizing diabetes management, offering patients a painless alternative. Recent standardization of accuracy guidelines by the Clinical & Laboratories Standard Institute bolsters the reliability of POC testing, especially in critical care environments. With an estimated 537 million people living with diabetes in 2021, forecast projections suggest this number could reach 783 million by 2045. The rising demand for glucose diagnostics and Short Turn-Around Testing (STAT) solutions reflects the healthcare sector's focus on improved patient care, efficiency, and compliance in managing glucose levels.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Glucose Tolerance Test market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Glucose Tolerance Test Market Segmental Analysis

Global Glucose Tolerance Test Market is segmented by Product Type, Disease Indication, End user and region. Based on Product Type, the market is segmented into Smart Sensors, Blood Glucose Testing Kit, Meters, Test Slips and Others. Based on Disease Indication, the market is segmented into Reactive Hypoglycemia, Diabetes Hypoglycemia, Gestational Diabetes, Insulin Resistance and Others. Based on End user, the market is segmented into Hospitals, Clinics, Diagnostic Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Glucose Tolerance Test Market

The global glucose tolerance test market is significantly driven by the escalating prevalence of diabetes across the globe. Factors contributing to this alarming rise include lifestyle alterations, such as decreased physical activity and unhealthy dietary choices, which in turn amplify the demand for reliable diagnostic tools like glucose tolerance tests. As the awareness surrounding diabetes continues to grow, so does the popularity of these tests, owing to their essential role in the early detection and management of the condition. Consequently, the increasing diabetes rates are compelling healthcare providers and patients alike to prioritize the utilization of glucose tolerance testing, propelling the market forward.

Restraints in the Global Glucose Tolerance Test Market

The global glucose tolerance test market faces significant constraints primarily due to the high costs associated with testing. Many individuals, particularly in economically disadvantaged regions, find these expenses prohibitive, which can lead to a reluctance to undergo essential diagnostic procedures. The financial burden stems from the prices of glucose testing kits, meters, and necessary accessories, along with the frequency of testing required to monitor glucose levels effectively. This situation may hinder market growth by discouraging patients from seeking vital testing services, ultimately affecting overall public health and the early detection of diabetes and related conditions.

Market Trends of the Global Glucose Tolerance Test Market

The Global Glucose Tolerance Test (GTT) market is experiencing significant growth due to advancing diagnostic technologies and increasing diabetes prevalence. As global populations age and unhealthy lifestyle choices rise, there is a marked increase in cases of diabetes and prediabetes, driving the demand for accurate diagnostic tools. Healthcare policies are also evolving to prioritize early intervention, highlighting the necessity for effective screening methods like the GTT. This burgeoning market is fueled by continual innovations in testing methodologies and an urgent need for reliable diagnostics, positioning GTT as a critical component in diabetes management strategies worldwide.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement

Global Glucose Tolerance Test Market Size by Product Type & CAGR (2025-2032)

• Market Overview
• Smart Sensors
• Blood Glucose Testing Kit
• Meters
• Test Slips
• Others

Global Glucose Tolerance Test Market Size by Disease Indication & CAGR (2025-2032)

• Market Overview
• Reactive Hypoglycemia
• Diabetes Hypoglycemia
• Gestational Diabetes
• Insulin Resistance
• Others

Global Glucose Tolerance Test Market Size by End user & CAGR (2025-2032)

• Market Overview
• Hospitals
• Clinics
• Diagnostic Centers
• Others

Global Glucose Tolerance Test Market Size & CAGR (2025-2032)

• North America (Product Type, Disease Indication, End user)
  • US
  • Canada
• Europe (Product Type, Disease Indication, End user)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Disease Indication, End user)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Disease Indication, End user)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Disease Indication, End user)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Thermo Fisher Scientific Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NIPRO (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Trividia Health, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dexcom, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Healius Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Penlan Healthcare Ltd. (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quest Diagnostics Incorporated (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Laboratory Corporation of America Holdings (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ARUP Laboratories (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cleveland HeartLab, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ascensia Diabetes Care Holdings AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• E-Zlab Health Services (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffman-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LifeScan IP Holdings, LLC (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations